---
title: Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes
nct_id: NCT01517555
overall_status: COMPLETED
phase: PHASE1
sponsor: Novo Nordisk A/S
study_type: INTERVENTIONAL
primary_condition: Diabetes
countries: Germany
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01517555.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01517555"
ct_last_update_post_date: 2017-01-26
last_seen_at: "2026-05-12T07:32:38.085Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes

**Official Title:** A Single Centre, Randomised, Double-blind, Placebo Controlled Trial to Evaluate the Possible Drug-drug Interaction Between Liraglutide and Paracetamol and the Effects of Liraglutide on Postprandial Glucose and Insulin, Gastric Emptying, Appetite Sensations and Energy Intake in Subjects With Type 2 Diabetes

**NCT ID:** [NCT01517555](https://clinicaltrials.gov/study/NCT01517555)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 18
- **Lead Sponsor:** Novo Nordisk A/S
- **Conditions:** Diabetes, Diabetes Mellitus, Type 2
- **Start Date:** 2006-10
- **Completion Date:** 2007-05
- **CT.gov Last Update:** 2017-01-26

## Brief Summary

This trial is conducted in Europe. The aim of this trial is to to investigate if there is a drug-drug interaction between liraglutide and paracetamol (Benuron®) and to investigate the effect of liraglutide on post prandial glucose.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 70 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Type 2 diabetes mellitus
* Diet-treated subjects with type 2 diabetes with HbA1c 7.5-9.5 %
* Subjects with type 2 diabetes in oral anti-diabetic drug (OAD) monotherapy treated with metformin or alpha-glucosidase inhibitors with HbA1c 7.0-9.5%
* Body mass index (BMI) 18.5-40 kg/m\^2
* Subjects should have a stable body weight for at least 3 months prior to screening (as judged by the Investigator)

Exclusion Criteria:

* Impaired liver function
* Impaired renal function
* Clinically significant active cardiovascular disease including history of myocardial infarction within the last 6 months and/or heart failure
* Any clinically significant abnormal ECG (electrocardiogram)
* Uncontrolled treated/untreated hypertension
* Recurrent severe hypoglycaemia as judged by the Investigator
* Active hepatitis B and/or active hepatitis C
* Positive human immunodeficiency virus (HIV) antibodies
* Known or suspected allergy to trial product(s) or related products
```

## Arms

- **Liraglutide** (EXPERIMENTAL)
- **Placebo** (PLACEBO_COMPARATOR)

## Interventions

- **liraglutide** (DRUG) — Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3
- **placebo** (DRUG) — Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
- **paracetamol** (DRUG) — One single dose of 1 g. Tablet

## Primary Outcomes

- **Area under the curve of paracetamol**
- **Area under the curve of post prandial plasma glucose**

## Secondary Outcomes

- **Area under the curve of paracetamol**
- **Cmax, maximum concentration**
- **tmax, time to reach Cmax**
- **t½, terminal half-life**
- **Terminal elimination rate constant**
- **Adverse events**

## Locations (1)

- Novo Nordisk Investigational Site, Neuss, Germany

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.novo nordisk investigational site|neuss||germany` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01517555.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01517555*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*